Etanercept biosimilar - Sandoz

Drug Profile

Etanercept biosimilar - Sandoz

Alternative Names: Erelzi; GP 2015

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sandoz
  • Class Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 21 Aug 2017 Launched for Rheumatoid arthritis, Ankylosing spondylitis and Juvenile rheumatoid arthritis in Canada (SC) - First Global Launch
  • 02 Aug 2017 The Canadian Drug Expert Committee as part of the Common Drug Review process issues a positive drug reimbursement recommendation for etanercept biosimilar in Inflammatory disorders
  • 27 Jul 2017 Launched for Ankylosing spondylitis, Juvenile rheumatoid arthritis, Plaque psoriasis, Psoriatic arthritis and Rheumatoid arthritis in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top